Research & Publications
Baseline Demographic and Clinical Characteristics of Patients Receiving Resmetirom, GLP-1 Agonist, and Combination Therapy for MASH: A Real-World U.S. Claims Analysis
Summary
This real-world claims analysis used Inovalon real-world data to characterize patients with MASH or MASLD who had claims for resmetirom, a GLP-1 receptor agonist (GLP-1 RA), or both. The data were Commercial, Medicare Advantage, and Managed Medicaid claims from March 2023 to March 2026. Researchers descriptively characterized demographics, cardiometabolic comorbidities, baseline liver tests and procedures, and prescriber specialty across three groups:
- 3,541 patients on resmetirom alone
- 2,963 with claims for both resmetirom and a GLP-1 RA
- 260,943 on a GLP-1 RA alone
Key Findings
- Nearly half of resmetirom-treated patients (45.6%) also had a GLP-1 RA claim during the study period, though not necessarily at the same time.
- Patients with claims for both therapies had the highest cardiometabolic comorbidity burden. Type 2 diabetes affected 82% of them, compared with 35% of patients on resmetirom alone and 75% on a GLP-1 RA alone.
- About 70% of patients in both resmetirom groups had liver elastography in the year before their first resmetirom claim. Among patients on a GLP-1 RA alone, 7% had elastography before their first GLP-1 RA claim.
- GI/hepatology specialists wrote about 40% of first resmetirom prescriptions, compared with 0.5% of GLP-1 RA monotherapy prescriptions. Specialty was listed as other or unknown for 46% to 49% of prescriptions in each group.
Why This Matters
Real-world use of resmetirom and GLP-1 RAs reflects distinct patient populations and care pathways. These patterns may reflect differences in cardiometabolic and liver-related clinical characteristics. The findings highlight opportunities for more integrated liver and cardiometabolic care, including fibrosis risk assessment and finding patients who may benefit from MASH-directed therapy. Future studies linking claims with EHR and laboratory data could assess fibrosis severity and compare outcomes and costs across treatment groups.
Read the Full Abstract:
https://www.aasld.org/sites/default/files/2026-10/2026%20TLM%20Abstracts.pdf
